Reuters logo
a year ago
CORRECTED-BRIEF-Onxeo H1 net loss narrows to 11.2 million euros (July 28)
July 29, 2016 / 11:46 AM / a year ago

CORRECTED-BRIEF-Onxeo H1 net loss narrows to 11.2 million euros (July 28)

(Removes reference to Livatag in headline of July 28 brief item)

July 29 (Reuters) - Onxeo SA :

* H1 net loss of 11.2 million euros ($12.40 million) versus loss of 11.3 million euros year ago

* H1 revenue 1.8 million euros versus 1.5 million euros year ago

* Livatag phase III trial in HCC: 80 pct of patients randomized

* First development steps of new oral formulation of Beleodaq

* 19.6 million euros cash-on-hand as of June 30, 2016 Source text for Eikon: Further company coverage: ($1 = 0.9033 euros) (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below